Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 2

Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder

NCT05600114 · View on ClinicalTrials.gov ↗

Study Summary

A phase 2, multicenter, double-blind, parallel group, placebo-controlled, randomized clinical study, designed to compare the efficacy, safety, and tolerability of 2 dose levels of CBD and a matching placebo for the treatment of subjects with Social Anxiety Disorder (SAD).

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Cannabidiol oral solution

Study Locations (17)

California

  • EPI-CBD-001 Site — Encino
  • EPI-CBD-001 Site — Lemon Grove
  • EPI-CBD-001 Site — Los Alamitos
  • EPI-CBD-001-Site — Oceanside
  • EPI-CBD-001 site — San Jose

Florida

  • EPI-CBD-001 Site — Jacksonville
  • EPI-CBD-001 Site — Lauderhill
  • EPI-CBD-001 Site — Maitland
  • EPI-CBD-001 Site — Orlando

New York

  • EPI-CBD-001 Site — Cedarhurst
  • EPI-CBD-001-Site — New York
  • EPI-CBD-001-Site — Rochester

Illinois

  • EPI-CBD-001 Site — Chicago

Oklahoma

  • EPI-CBD-001 Site — Oklahoma City

Oregon

  • EPI-CBD-001 Site — Portland

Texas

  • EPI-CBD-001 site — Wichita Falls

Washington

  • EPI-CBD-001 Site — Bellevue

Trial Details

FieldValue
Enrollment Target 239 participants
Start Date 2022-10-27
Est. Completion 2023-12-13
Phase Phase 2

Sponsor

EmpowerPharm

1 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05600114

The ClinicalTrials.gov registry entry for NCT05600114 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 239 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EmpowerPharm, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Social Anxiety Disorder appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05600114 reports 17 study locations spanning 8 distinct geographic areas — top geographies include California, Florida, New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05600114 about?

NCT05600114 is a clinical study titled "Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder". A phase 2, multicenter, double-blind, parallel group, placebo-controlled, randomized clinical study, designed to compare the efficacy, safety, and tolerability of 2 dose levels of CBD and a matching placebo for the treatment of subjects with Social Anxiety Disorder (SAD).

What is the current status of trial NCT05600114?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 239 participants. The study started on 2022-10-27. Estimated completion is 2023-12-13.

What conditions does trial NCT05600114 study?

This clinical trial studies the following conditions: Social Anxiety Disorder. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05600114?

The interventions under investigation include: Placebo (DRUG), Cannabidiol oral solution (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05600114?

This trial is sponsored by EmpowerPharm, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05600114 being conducted?

This trial has 17 study locations across California, Florida, Illinois, New York, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial